Padsevonil + Placebo
Phase 3Terminated 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Drug-Resistant Epilepsy
Conditions
Drug-Resistant Epilepsy, Focal-Onset Seizures
Trial Timeline
Mar 6, 2019 → Sep 28, 2020
NCT ID
NCT03739840About Padsevonil + Placebo
Padsevonil + Placebo is a phase 3 stage product being developed by UCB for Drug-Resistant Epilepsy. The current trial status is terminated. This product is registered under clinical trial identifier NCT03739840. Target conditions include Drug-Resistant Epilepsy, Focal-Onset Seizures.
What happened to similar drugs?
1 of 1 similar drugs in Drug-Resistant Epilepsy were approved
Approved (1) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
17
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03739840 | Phase 3 | Terminated |
Competing Products
6 competing products in Drug-Resistant Epilepsy
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| OnabotulinumtoxinA 145 UNT [Botox] | AbbVie | Approved | 35 |
| Delamanid + Levofloxacin + Bedaquiline + Clofazimine + Linezolid | Novartis | Phase 2 | 42 |
| UCB0942 | UCB | Phase 2 | 27 |
| Padsevonil | UCB | Phase 2 | 27 |
| UCB0942 + UCB0942 + Placebo | UCB | Phase 2 | 35 |
| Padsevonil | UCB | Phase 2 | 35 |